MBrace Therapeutics
MBrace Therapeutics is a privately held, clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) against novel oncology targets. Co-founded by Renata Pasqualini, Ph.D. and Isan Chen, MD, the company builds its pipeline on SPARTA, an in vivo antibody selection and target discovery process it uses to find ADC targets that conventional in vitro discovery misses. Its lead candidate MBRC-101 is an anti-EphA5 monomethyl auristatin E (MMAE) antibody-drug conjugate in a multi-centre, open-label Phase 1/1b dose-finding, safety and pharmacokinetic study in advanced refractory solid tumours; MBRC-201 is in Phase 2, MBRC-301 is in IND-enabling studies against solid tumours, and MBRC-401 is in discovery. MBrace emerged from stealth in November 2023 with an $85 million Series B led by TPG through TPG Life Sciences Innovations, alongside Avidity Partners, Blue Owl Capital, Venrock and Alta Partners, bringing total capital raised to $110 million. MBRC-101 was named Most Promising Clinical Candidate at the 11th Annual World ADC Awards. MBrace Therapeutics runs no developer program and publishes no product API, developer portal, API reference or SDK. The only machine-readable surface reachable without credentials is the WordPress REST content API behind mbracetrx.com, catalogued here — notable because the company registered five of its own custom post types, so its board, executive committee, founders, named investors and scientific advisory board are all published as structured JSON rather than only as rendered HTML.
MBrace Therapeutics publishes 9 APIs on the APIs.io network, including Discovery API, Media API, News API, and 6 more. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Antibody-Drug Conjugates.
MBrace Therapeutics’ developer surface includes product news, authentication, and 26 more developer resources.
Kin Score
APIs 9
Individual APIs this provider publishes, each with its own machine-readable definition.
MBrace Therapeutics Discovery API
Route, type, taxonomy and status discovery documents.
MBrace Therapeutics Media API
Media library (224 attachments at harvest time).
MBrace Therapeutics News API
Company news archive — press releases, scientific presentations and publications (8 published at harvest time, spanning November 2023 through July 2025).
MBrace Therapeutics Oembed API
oEmbed 1.0 provider endpoint for mbracetrx.com URLs.
MBrace Therapeutics Pages API
Corporate site pages (12 published at harvest time).
MBrace Therapeutics People API
The five company-specific custom post types MBrace Therapeutics registered for its own governance and backer disclosures: board members, executive committee, founders, investors...
MBrace Therapeutics Search API
Cross-content search across every published object on the deployment (76 searchable objects at harvest time).
MBrace Therapeutics Taxonomy API
Category and tag terms. Four categories are registered; the post_tag taxonomy is registered but empty.
MBrace Therapeutics Users API
Post authors exposed by the users collection (3 at harvest time).
Scroll for all 9
Pricing Plans 1
Published pricing tiers and plan structures.
Rate Limits 1
Documented rate limits and quota policies.
Mbrace Therapeutics Rate Limits
RATE LIMITSSecurity Posture 2
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 2
MCP servers, agent skills, and machine-readable catalogs
Design & Contract 5
Pagination, idempotency, versioning, errors, and events
Build 3
SDKs, sample code, and the tooling you integrate with
Access & Security 2
Authentication, authorization, and security posture
Operate 2
Status, limits, changes, and where to get help
Commercial 3
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
Other 6
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.